Science 37
Rob has been a Managing Director at Redmile Group, LLC, a healthcare-focused investment firm, since February 2008. Prior to Redmile, Rob was a sell-side equity analyst for 16 years, from 1992 to 2008, including at Hambrecht & Quist (now JPMorgan), Thomas Weisel Partners (now Stifel Financial Corp.), and SG Warburg & Co. (now UBS). He has also served as a director of MedAvail Holdings, Inc. since November 2020. Rob received a Bachelor of Arts in Government in 1984 from Harvard College and a Master of Business Administration from the Tuck School of Business at Dartmouth College in 1990.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Science 37
2 followers
Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representative patient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials.